Recently, autophagy-related proteins were shown to regulate osteoclast mediated bone resorption, a critical process in autoimmune diseases such as rheumatoid arthritis. However, the role of autophagylinked FYVE containing protein, WDFY3, in osteoclast biology remains elusive. WDFY3 is a master regulator in selective autophagy for clearing ubiquitinated protein aggregates and has been linked with rheumatoid arthritis. Herein, we used a series of WDFY3 transgenic mice (Wdfy3 lacZ and Wdfy3 loxP ) to investigate the function of WDFY3 in osteoclast development and function. Our data demonstrate that WDFY3 is highly expressed at the growth plate of neonatal mice and is expressed in osteoclasts in vitro cultures. Osteoclasts derived from WDFY3 conditional knockout mice (Wdfy3
Introduction
Bone remodeling is a dynamic process, which maintains skeletal homeostasis and entails the removal of old bone and its replacement with new. Two types of cells with opposing functions regulate this process; the osteoclasts, that resorb bone and the osteoblasts that form new bone. Dysregulation of skeletal homeostasis leads to musculoskeletal diseases. These disorders are characterized by loss of bone and joint function that require extensive treatment and long periods of recovery. Bone destruction in musculoskeletal conditions is primarily caused by an imbalance between bone resorption and bone formation. Changes in the number and/or activity of osteoclasts/osteoblasts may be a direct reflection of musculoskeletal diseases [1] and [2] .
Osteoclasts are multinucleated cells (MNCs) derived from myeloid progenitor cells. Macrophage colony-stimulating factor (M-CSF), and receptor activator of NF-kB ligand (RANKL) regulate the differentiation of osteoclasts [3] . M-CSF stimulation leads to phosphorylation of AKT and ERK, which promotes proliferation and survival in osteoclast precursor cells [4] . RANKL/RANK interaction recruits TRAF6 to activate IΚΚb, which phosphorylates IkBa (inhibitor of NF-kB) and leads to its degradation. NF-kB then is released from IkBa-NF-kB complex, and translocates into the nucleus, and activates genes required for osteoclast differentiation [5] . TRAF6 has indispensable roles for osteoclastogenesis since the absence of the protein leads to osteopetrosis in vivo [6] and [7] . Terminally differentiated osteoclasts undergo cytoskeletal reorganization to facilitate the formation of filamentous-actin (F-actin) ring structures. The extracellular matrix, within the F-actin ring, is acidified by a vacuolar ATPase which is facilitated by carbonic anhydrase II, a crucial enzyme that acts as a proton source by catalyzing the hydration of carbon dioxide to carbonic acid [8] and [9] . Activated osteoclasts secrete bone-degrading enzymes CTSK, MMP9, TRAP into the sealing zone through the ruffled border, a specialized cellular structure that provides increased surface area to facilitate vesicles secretion [10] .
WDFY proteins, WDFY1, WDFY2, WDFY3 and WDFY4, are novel proteins that contain WD40 repeats. All of WDFY family proteins contain WD40 repeats and WDFY1, 2 and 3 contain a FYVE domain, which is associated with vacuolar/lysosomal trafficking. WDFY1 and WDFY2 are medium size proteins (around 400 amino acids) and have been associated with endosomal pathway [11] and [12] . WDFY3 and WDFY4 are large proteins (>3000 amino acids) and contain PH and BEACH domains. Recently two independent genome-wide association studies revealed two SNP's rs2671692 and rs1913517 in WDFY4 associated with rheumatoid arthritis [13] and systemic lupus erythematosus [14] respectively. WDFY3 has recently been reported as a master regulator of selective autophagy [15] and [16] . Autophagy is a highly conserved cellular pathway for protein degradation. Loss of autophagy proteins has been shown to prevent joint destruction in a mouse arthritis model [17] and bone destruction in a mouse osteoporosis model [18] . Interestingly, association between WDFY3 expression and autoimmune diseases has been observed in patients with rheumatoid arthritis [19] . Moreover, WDFY3 expression has been clearly documented in human osteoclasts, the cells responsible for bone degradation [20] .
WDFY3 is expressed ubiquitously and is predicted to encode for 15 isoforms. However, we found only WDFY3 isoform a (3508 amino acids) is expressed in bone marrow while other isoforms mainly express in other tissues such as brain and testis using NCBI database [21] . WDFY3 contains several functional domains: a Pleckstrin homology (PH) domain, a Beige and Chediak-Higashi (BEACH) domain, five WD-40 repeats, and a typical FYVE domain [22] . PH-BEACH domain containing proteins are involved in vesicle trafficking and receptor signaling. Functionally, the WDFY3 BEACH domain interacts with the adaptor protein SQSTM1 to link the cargo to the autophagic machinery and elicit directed autophagosome formation. WD-40 repeats mediate the essential interaction with ATG5 in selective autophagy and vesicle trafficking [23] . The FYVE domain functions in membrane recruitment of cytosolic proteins by binding to phosphatidylinositol 3-phosphate (PI3P). Although the role of WDFY3 in selective autophagy has been elegantly demonstrated, the role of WDFY3 in rheumatoid arthritis associated pathologies such as bone destruction remains largely unknown.
In this report, we investigate the function of WDFY3 in osteoclasts in vitro and in vivo. Our data highlight a novel role for WDFY3 in osteoclast development and function.
Methods

Antibodies and reagents
All cell incubations were performed in culture medium consisting of aMEM with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 IU/ml Penicillin and 100 IU/ml Streptomycin (Life Technologies, 10007D). Mouse soluble RANKL (R&D Systems, 462 TR) and M-CSF ELISA (R&D Systems, DY416), RANKL ELISA (R&D Systems, DY462), and TRAF6 inhibitor (Novus, NBP2-26506) were used for in vitro experiments. CMG14-12 (CMG) media was generated as described before [24] . Collagenase type II (Calbiochem, 234155), dispase (Stem Cells Technologies, 07923), ascorbic acid (Sigma, A8960) and dexamethasone (Sigma, D4902) were used for osteoblast differentiation assays. AlamarBlue solution (Life Technologies, DAL1025) was used for cell viability assay. For western blot analysis and immunofluorescence staining, anti-IkBa (Cell Signaling, 4812), anti-phospho-IkBa (Cell Signaling, 2859P), anti-NF-kB p65 (Cell Signaling, 4764), and anti-phospho-NF-kB p65 (Cell Signaling, 3033P), anti-Src (Millipore, 05e184), and phospho-Src (Millipore, 07e909), anti-WDFY3 (Novus, NBP1-03332), anti-TRAF6 (Santa Cruz Biotechnology, clone D-10), anti-b-actin antibody (Cell Signaling, 4970), 800 or 680 secondary antibodies (Li-Cor). For flow cytometry, APC anti-mouse c-Fms and PE anti-RANK antibodies (Biolegend) were used for cell staining.
Mice and bone cell culture
Animal experiments were conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee of the University of California, Davis. Eight to twelve weeks old C57BL/6 (The Jackson Laboratory), Wdfy3
loxP/loxP animals were sacrificed to extract bone marrow from both rear femurs and tibias bones. Generation of Wdfy3 lacZ , Wdfy3 loxP animals is described in previous study [25] .
Bone marrow cells were cultured with 1:20 (v/v) CMG media in absence or presence of 30 ng/mL RANKL. Media and cytokines were exchanged every other day. For X-gal staining, neonate C57BL/6 or Wdfy3 lacZ/þ were sacrificed and sectioned for histology.
For osteoblast culture, cells were isolated from Wdfy3-cKO or wild type newborn mice calvaria by three sequential collagenase/ dispase digestions. Primary osteoblasts were expended in aMEM with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 IU/ml penicillin, and 100 IU/ml streptomycin until they were confluent before any use. Upon confluence, cells were seeded at 1 Â slides. Slides were incubated in X-gal staining solution (1 mg/ml Xgal, 5 mM potassium ferricyanide, 5 mM potassium ferryocyanide) overnight at room temperature. Fast red nuclear stain (Vector Labs) was used to counter stain nuclei in cell bone marrow cell culture. Fluoromount-G (Southern Biotech, 0100-01) was used to mount sample with cover glasses.
RNA extraction and real-time quantitative PCR
Total RNA was purified from different stages of osteoclast cultures using the RNAeasy Mini Kit (Qiagen). Gene expression was calculated using the 2 ÀDDCt method. qPCR primers used in the study:
Assessment of osteoclast formation
TRAP staining was performed according to manufacture's instruction with Acid phosphatase, Leukocyte (TRAP) Kit (Sigma, 387A). Briefly, macrophages or mature osteoclasts were first fixed in the acetone with citrate. Naphthol AS-BI phosphate was added as substrate for TRAP and produce insoluble pink dye. Cells grew on glass coverslips were fixed with 4% formaldehyde for 5 min and then permeabilized for 6 min in 0.5% Triton X-100 (in PBS) and rinsed with PBS to detect F-actin ring structure. The cells on coverslips were then incubated with phalloidin for 30 min, washed and rinsed with PBS before mounted with DAPI (Vector Laboratories, H1200), and observed using a fluorescence microscope (Nikon). Functional evidence of osteoclast formation was determined by a lacunar resorption assay system using cell cultures on dentine slices as previously described [26] . Cells were removed from the dentine slices by treatment with 10% Triton-X with sonication. The dentine slices were washed in distilled water and ultrasonicated to remove adherent cells, then stained with 1% (v/v) toluidine blue to reveal areas of lacunar resorption and examined by light microscopy. The pit area was quantified using NIH image analysis program ImageJ.
Scanning electron microscopy (SEM)
Functional evidence of osteoclast differentiation was obtained by a lacunar resorption assay system in which cells are cultured on dentine slices as previously described [27] . Dentine provides a smooth-surface mineralized substrate for the identification of lacunar resorption pits, which are only formed by osteoclasts. After BMMs were cultured on dentine slices for 7e10 days, the slices were removed from the wells and fixed in 4% glutaraldehyde or cells were removed from the dentine slices by treatment with 10% Triton-X with sonication. The dentine slices were dehydrated by passing through graded alcohols and then through graded hexamethyldisilazane solution (Electron Microscopy Sciences, 16700) before being air-dried. Dentine slices were then mounted onto aluminum stubs using double-sided carbon adhesive tabs, sputtercoated with gold and examined using a Philips XL30 TMP scanning electron microscope.
Immunofluorescence staining
Osteoclasts grown on coverslip were imaged by Nikon C1 confocal microscopy after fixation in 4% paraformaldehyde for 10 min. Cells were permeabilized in 0.2% Triton X-100 and blocked with 10% normal donkey serum buffer in PBS for 2 h at room temperature. All antibodies were diluted in 5% normal donkey serum buffer in PBS. Primary antibodies were applied on samples overnight at 4 C. Secondary antibody AF-488 donkey and antimouse Ig or AF-594 donkey anti-rabbit Ig antibodies were added to samples for 1 h incubation at room temperature. TRITC conjugated phalloidin was used for F-actin staining for 30 min incubation at room temperature. Coverslips were then mounted in mounting media with DAPI (Vector Laboratories, H1200) to stain nuclei. The size of multinucleated cell was quantified using NIH image analysis program ImageJ.
Co-immunoprecipitation
Osteoclast-like cells cultured from 8 to 12 weeks old wild type mice were lysed in lysis buffer consisting of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% v/v Triton X-100 containing protease inhibitor cocktail tablet (Roche, 4693124001). The clear lysate was incubated with anti-Wdfy3 antibody overnight and was then Coimmunoprecipitated by dynabeads protein A immunoprecipitation kit (Life technologies, 10006D).
Western analysis
Bone marrow-derived macrophages and osteoclast-like cells starved in serum-free medium were stimulated with RANKL (100 ng/ml) or M-CSF (100 ng/ml) and lysed at indicated time points. Protein lysates obtained from cell cultures were run on a Nu-Page 3e8% Tris-Acetate gel, 4e12% Bis-Tris gel or 12% Bis-Tris gels (Invitrogen). Proteins were transferred to PVDF membranes and blocked in Odyssey blocking buffer. Membranes were incubated with anti-Wdfy3 primary antibody diluted in Odyssey blocking buffer containing 0.1% Tween-20, overnight at 4 C. After washing, we incubated with secondary antibody (Li-Cor) in blocking buffer containing 0.1% Tween-20 and 0.02% SDS, washed, and imaged on the Li-Cor Odyssey scanner. The process was repeated with b-actin as loading control. Signal intensity relative to background was determined using Li-Cor Image Studio software.
Microarray analysis
Total RNA was amplified and purified using an Ambion Illumina RNA amplification kit (Ambion) to yield biotinylated cRNA and 1.5 mg of cRNA samples were hybridized to Illumina WG-6 v2.0 chips according to manufacturer's instructions. Arrays were scanned by Illumina iScan. Raw data were extracted using the software provided by the manufacturer (Illumina GenomeStudio). Probe signal value was transformed by mean normalization and logarithm, and then illustrated by heat map. Go-ontology analysis for the list of significant probes was performed using PANTHER (http:// www.pantherdb.org/panther/ontologies.jsp), using text files containing gene.
Flow cytometry of bone marrow derived macrophages
Bone marrow cells were isolated from Wdfy3-cKO or wild type mice and were cultured with 1:20 (v/v) CMG media for 4 days. Nonspecific binding was blocked by pretreating cells with rat antimouse CD16/32 mAb (Biolegend, clone 93) for 10 min on ice. Cells were stained using predetermined optimized mAb concentration, and events were collected on a FACSAriaII flow cytometer (BD Biosciences) and were analyzed using FlowJo software (Tree Star).
RANKL gene transfer model
RANKL gene transfer was performed as described previously [28] . Briefly, 5 mg of RANKL or GFP minicircles were delivered to experimental mice in~10% of mice body weight of warm Ringer's solution via tail veins in 5e7 s. The soluble RANKL level in serum was monitored using mouse RANKL ELISA. Serum TRACP 5b was monitored by MouseTRAP EIA assay (Immunodiagnostic System, SB-TR103) and serum CTX-I was measured by RatLaps (CTX-I) EIA assay (Immunodiagnostic System, AC-06F1).
Trabecular bone analysis by micro-computed tomography imaging
Fixed mouse skeletons were imaged at the Center for Molecular and Genomic Imaging (UC Davis) in order to visualize full-body skeletal structure. Mouse skeletons were imaged in ethanol in 50 mL conical vials. The vials were secured in place using a custom plastic holder to prevent any movement during the scan. X-ray tomographic images were obtained on the MicroXCT-200 specimen CT scanner (Carl Zeiss X-ray Microscopy) using the Xradia LE3 filter, Distal femurs were imaged with micro-computed tomography (SCANCO mCT 35) to quantify trabecular bone structure in the distal femoral metaphysis. Dissected limbs were fixed in 4% paraformaldehyde for 24e48 h, and then transferred to 70% ethanol. Knees were scanned according to the guidelines for microcomputed tomography (mCT) analysis of rodent bone structure [29] (X-ray tube potential ¼ 55 kVp, intensity ¼ 114 mA, 6 mm isotropic nominal voxel size, integration time ¼ 900 ms, number of projections ¼ 1000/180 ). Trabecular bone of the distal femoral metaphysis was analyzed by manually drawing contours on 2D transverse slices. The volume of interest was 0.9 mm (150 slices) immediately adjacent to the distal epiphyseal growth plate. Trabecular bone was segmented from non-bone using a global threshold of 543.9 mg HA/cm 3 ; this threshold was determined based on histograms of pixel brightness for the volumes of interest and visual comparison with unsegmented images. We quantified trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), apparent bone mineral density (Apparent vBMD; mg HA/cm 3 TV) and other parameters using the manufacturer's analysis tools.
Statistical analyses
Statistical significance was determined using Student's t-test and p-values lower than 0.05 were considered significant.
Results
WDFY3 is expressed in bone tissue and osteoclasts
To analyze the expression of WDFY3 in bone tissue, we employed a Wdfy3 lacZ line previously generated by gene targeting [25] (Fig. 1A, right panel) . No b-gal staining was detected as expected in the control wild type tissue sections (Fig. 1A, left panel) . -LysM-Cre mice (referred as Wdfy3-cKO mice in this manuscript). The loss of WDFY3 in our Wdfy3-cKO was verified by western blotting on isolated myeloid cells where~85% of WDFY3 is knocked out in mutant animals compared to wild type animals (Fig. 1C) . Immunofluorescence staining demonstrated a ubiquitous expression of WDFY3 (green) in wild type BMMs and multinucleated giant cells (Fig. 1E, H) . We observed WDFY3 expression in the cytosol, which also localized at the edge of filamentous actin ring (red) structures in the wild type multinucleated giant cells (Fig. 1H) . We observed minimal WDFY3 (green) signal in Wdfy3-cKO cells, which may be due to non-specific binding of the antibody (Fig. 1F, I ) and did not observe WDFY3 signal in the wild type cells stained with isotype control (Fig. 1D, G) .
Loss of WDFY3 does not alter cell viability in bone marrowderived macrophages
Next, we investigated whether WDFY3 deficiency influences osteoclast precursor cells. Interestingly, we did not observe any differences between Wdfy3-cKO and wild type BMMs in the survival of osteoclast precursor populations, or expression of protein in c-Fms and RANK receptors as evidenced by alamar blue assay ( Fig. 2A) and flow cytometric analysis (Fig. 2B) . Phosphorylation of AKT and ERK, associated with cell survival pathways, was also similar between WDFY3-deficient and wild type BMMs in timecourse stimulation with 100 ng/ml M-CSF (Fig. 2C) . To identify potential differences in macrophages and osteoclasts derived from Wdfy3-cKO and wild type cultures, we performed microarray analysis on Wdfy3-cKO and wild type cultures treated with or without RANKL.
In agreement with our data generated by flow cytometry, western blotting and survival assays we did not observe significant differences in macrophage cultures using the Illumina WG-6 v2.0 chip (data not shown). However, WDFY3-deficient BMMs ActB, Cx3cr1, Lcn2, Lyz and Pglyrp1 gene expression were different from wild type BMMs. Interestingly, we observed down-regulation of genes associated with cytoskeleton, extracellular matrix, and metabolic pathways in Wdfy3-cKO BMM culture treated with RANKL compared to wild type culture (Fig. 2D ). As these genes are critical for osteoclast function we next performed osteoclast functional assays.
Loss of WDFY3 in myeloid cells leads to enhanced osteoclastogenesis in vitro
In osteoclast assays, bone marrow-derived macrophages were treated for 5 days with 30 ng/ml of RANKL. WDFY3 deficiency resulted in earlier formation of TRAP þ cells compared to wild type cultures (Fig. 3A, B, K) . Furthermore, consistent with this enhanced osteoclastogenesis we observed that WDFY3-deficient cells also formed larger multi-nucleated TRAP þ cells in 7-day cultures compared to wild type cells (Fig. 3C, D, L) . In addition to the increased size of TRAP þ multinucleated cells (MNCs), Wdfy3-cKO also were capable of F-actin ring formation and had larger cell perimeters (Fig. 3E, F, M) . To access osteoclast function, and observe detailed morphological differences, we further cultured BMMs on dentin slices and visualized with scanning electron microscopy (SEM). Osteoclasts cultured from wild type or Wdfy3-cKO mice were large (~200 mm), flattened, and spread over the dentine surface to which they were attached by fine microvilli (Fig. 3G and H) . Lacunar resorption was noted after 10 days of treatment with RANKL; in the absence of RANKL, no lacunar resorption was detected. Interestingly, Wdfy3-cKO osteoclasts demonstrated increased activity in dentine resorption assays compared to wild type osteoclasts (Fig. 3I, J, N) . In agreement with these observations, gene expression data also demonstrated an increase in osteoclast specific genes including Ctsk, Mmp9, Acp5, Nfatc1, and Itgb3 (Fig. 3O) . No significant changes were observed in p62, autophagy-related genes Atg5 and Atg7, and deubiquitinase gene Cyld in WDFY3-deficient cells compared to wild type cells (Supplementary Fig. 2 ).
WDFY3 modulates NF-kB activity via up-regulation of TRAF6
Since we observed enhanced osteoclastogenesis in our in vitro assays, we hypothesized that loss of WDFY3 might affect the RANKL signaling pathway which is the major pathway for osteoclast differentiation and function. We first cultured bone marrow cells from Wdfy3-cKO or wild type mice in the presence of M-CSF and performed a dose response 0, 7.5, 15 and 30 ng/ml of mouse sRANKL (Fig. 4A) . We observed increased osteoclast differentiation in the presence of low dose RANKL in WDFY3-deficient BMMs compared to wild type cells. In keeping with these data, total cell lysates from WDFY3-deficient multinucleated giant cells stimulated with RANKL (100 ng/ml) also demonstrated enhanced phosphorylated IkBa degradation and increased phosphorylated NF-kB p65 after 5 min of RANKL stimulation (Fig. 4B) . Src phosphorylation patterns demonstrated no significant differences between Wdfy3-cKO and wild type mice (Fig. 4B) . Consistent with RANKL-hyperactivation in WDFY3-deficient BMMs we also observed a discrepancy in the expression of TRAF6 at both message and protein level between WDFY3-deficient cells compared to wild type cells cultured in the presence of RANKL (Fig. 4C, D) .
WDFY3 interacts with TRAF6 in TRAP þ MNCs
To investigate the interaction of WDFY3 and TRAF6 in osteoclasts, we performed WDFY3 co-immunoprecipitation (co-IP) of total cell lysates derived from RANKL-treated cultures and immunoblotted with anti-WDFY3 and anti-TRAF6 specific antibodies. Our results indicated an interaction of WDFY3 and TRAF6 in MNCs (Fig. 5A) . To further examine these interactions, we labeled BMMs and multinucleated giant cells with immunofluorescence antibodies, anti-WDFY3 (red), anti-TRAF6 (green), and DAPI (blue), and examined the cells under confocal microscopes. In agreement with the co-IP data, we observed that WDFY3 and TRAF6 colocalize in both cell types (Fig. 5B and C) . Collectively, these findings confirm WDFY3 and TRAF6 interaction in the bone marrow-derived macrophages and multinucleated giant cells. To examine whether the increased osteoclast differentiation in WDFY3-deficient cells is TRAF6 dependent, we treated wild-type or WDFY3-deficient osteoclast culture with TRAF6 inhibitor at 25, 50, 100 mM (Fig. 5D ). We observed a dose dependent reduction of TRAP þ MNCs (Fig. 5E ) that suggested the enhanced osteoclast differentiation in WDFY3-deficient cells is TRAF6 dependent.
3.6. Loss of WDFY3 exacerbates bone loss in the RANKL gene transfer model
To address the role of WDFY3 in osteoclast differentiation and function in vivo, we used RANKL gene transfer to overexpress RANKL in vivo as previously described [28] . RANKL-gene transfer induced similar systemic levels of serum RANKL in both Wdfy3-cKO and wild type littermates at day 7-post gene transfer (Fig. 6A) . However, despite the equal serum levels of RANKL we detected a marked increase in serum TRACP 5b, which correlated with higher numbers of osteoclasts, and CTX-I, a bone resorption marker, in comparison to GFP gene transfer animals at day 7-post gene transfer (Fig. 6B, C) . To identify a functional significance of these changes we performed whole body MicroCT scans, where we observed reduced bone density (Fig. 6D) . To evaluate these findings, we performed quantitative high resolution MicroCT analysis at distal femurs of Wdfy3-cKO mice and compared to wild type littermates at day 30-post gene transfer. We found that trabecular bone volume fraction (BV/TV) was decreased and trabecular separation (Tb. Sp) was increased significantly in RANKL gene transfer Wdfy3-cKO compared to wild type littermates 30 days post gene transfer. We also observed a trend towards decreased trabecular thickness (Tb. Th) (p ¼ 0.2112), and trabecular number (Tb. N) (p ¼ 0.2038) in RANKL gene transfer Wdfy3-cKO compared to wild type (Fig. 6EeI) . Moreover, we found no difference between WDFY3-deficient osteoblast cultures compare to wild type osteoblast cultures by ALP staining (Supplementary Fig. 1B ) and ALP activity assay (Supplementary Fig. 1C ). Collectively, these findings confirmed loss of WDFY3 leads to exacerbated bone resorption compared to wild type mice in vivo.
Discussion
The ubiquitin-proteasome system (UPS) and autophagy are the two main protein degradation pathways in mammalian cells. In the UPS system, damaged or unwanted proteins are labeled with ubiquitin and later degraded by the proteasome [30] . During autophagy, damaged or unwanted proteins are recruited into an autophagosome, which subsequently fuses with lysosomes to form an autolysosome, where protein degradation takes in place [31] . Although autophagy has been considered to be non-selective process, accumulating recent evidence demonstrate that autophagy also encompasses highly selective degradation processes with high specificity such as clearing damaged mitochondria (mitophagy) and clearing ubiquitinated protein aggregates (aggrephagy) [32] . WDFY3, also known as autophagy-linked FYVE containing protein (ALFY), is a highly conserved and ubiquitously expressed protein across species that plays an essential role in selective autophagy [22] . In selective autophagy, WDFY3 forms a complex with Sequestosome1 (SQSTM1) to recruit ubiquitinated protein aggregates. The WDFY3/SQSTM1 complex also recruits the autophagy related protein 7 (ATG7) activated ATG5-ATG12 complex, and ATG7 lapidated LC3II to form an autophagosome which subsequently fuses with the lysosome (autolysosome) for protein degradation [15] [16] , and [23] . Interestingly, deficiency in ATG5 or ATG7 in mice leads to impaired ruffled border formation in osteoclasts, leading to defective secretory function and reduced bone resorption independently from their known function in autophagy [18] . Similarly, a mutation in WDFY3 in mice had no detectable difference in autophagosome formation and ubiquitinated protein expression in developmental brain compared to wild type mice [25] . In keeping with these observations we did not observe difference in autophagy-related gene expression nor starvation-induced autophagy (data not shown) between WDFY3-deficient and wild type pre-osteoclasts. These data suggest that WDFY3 may also have autophagy independent roles in osteoclast biology similar to the aforementioned ATG5/7 proteins, which merits further investigation.
Deficiency in WDFY3 orthologues in mice and Drosophila has been associated with neurodegenerative and developmental disorders [25] and [33] . While multiple WDFY3 isoforms are predicted, their function is yet to be elucidated and it is not clear whether WDFY3 has other roles beyond selective autophagy and may contribute to diseases of the musculoskeletal system. This is particularly important as recent clinical studies suggested that WDFY3 also regulates the survival of rheumatoid arthritis synovial fibroblasts, which is paramount in pannus formation and synovial inflammation in rheumatic diseases [19] . Other groups have shown WDFY3 co-localized with SQSTM1, a protein implicated in Paget's disease of bone, in human osteoclasts [20] . Due to these observations we investigated the expression of WDFY3 using Wdfy3 lacZ mice, and found that indeed WDFY3 is expressed in both osteoclasts and osteoblasts and its prominently expressed within the growth plate which is the most active bone remodeling site.
WDFY3 deficiency resulted in an increased osteoclast differentiation and activation compared to wild type cells using functional osteoclast assays. In agreement with these functional assays, we also observed up-regulation of osteoclast specific genes Ctsk, Mmp9, and Acp5 in WDFY3-deficient cells compared to wild type cells. The increased osteoclast differentiation was not due to variations of c-Fms, RANK expression that might sensitize a specific population to proliferation or differentiation signals. This was further confirmed in our survival and viability assays in WDFY3-deficient osteoclast precursor cells. Instead, the increased osteoclast differentiation could be due to an up-regulation of TRAF6 accompanied by enhanced NF-kB signaling in WDFY3-deficient osteoclasts. We then further confirmed Wdfy3 and TRAF6 interaction in the osteoclasts which is in agreement with another group's findings in HeLa cells where WDFY3 forms complex with TRAF6 for midbody ring degradation by selective autophagy [34] . Our observation of WDFY3 role in TRAF6-dependent osteoclast differentiation is interesting as TRAF6 also regulates IL-1 and TLR signaling pathways where TRAF6 binds to IRAK family members such as IRAK 1, 2, 4 and leads to NF-kB activation [7] and [35] . Although we did not observe difference in IRAK family members expression between Wdfy3-cKO and wild type mice in our microarray analysis, it remains a possibility that higher level of TRAF6 in Wdfy3-cKO mice may also contribute to activation of innate immunity that required further studies.
Using a newly developed in vivo RANKL gene transfer model [28] , we further identified increased bone loss in Wdfy3-cKO mice post RANKL gene transfer by high resolution MicroCT analysis accompanied with up-regulation of serum TRACP 5b (which correlated to a higher number of osteoclasts), and CTX-I (a bone resorption marker) compared to wild type littermates. These observations were most likely not caused by reduced bone formation since we did not observe any difference between WDFY3-deficient osteoblasts and the wild type cells in our osteoblast functional assays as shown in our Supplementary data. The increased osteoclast activation in Wdfy3-cKO mice demonstrated close resemblance with CYLD À/À mice, where loss of deubiquitinase CYLD led to osteopenia due to constant activation of TRAF6 [36] . We did not observe WDFY3-deficient cells altered Cyld expression at the mRNA level, which suggests Wdfy3 may be a novel negative regulator in RANKL signaling pathway. Apart from the regulation of TRAF6 in osteoclasts, WDFY3-deficient osteoclasts demonstrated a down-regulation of cytoskeleton genes Acta1, Actn2, Tnni2 and Tcap in our microarray analysis. This is interestingly similar to a recent human synovium microarray analysis that demonstrated down-regulation of Acta1, Actn2 Tnni2, and Tcap in rheumatoid arthritis (RA) patients compared to spondylarthritis (SpA) patients [37] . WDFY3-deficient osteoclasts also exhibited a down-regulation of several extracellular matrix protein genes including Mmp2. This is also intriguing as mutation or loss of Mmp2 have been implicated in inflammatory arthritis and bone destruction [38] and [39] . Furthermore, we also observed a downregulation of metabolic pathway genes and extracellular matrix genes such as Car3 (carbonic anhydrase 3) and Sparc (Osteonectin) with possible roles in musculoskeletal diseases [40] and [41] . However these gene expression profiles and their functional roles merit further investigation.
Collectively, our data provide a novel association between WDFY3 and the RANKL-induced osteoclastogenesis pathway via the modulation of TRAF6. Such regulation of osteoclast formation via WDFY3 can be critical for understanding and designing the therapeutic interventions for the treatments of rheumatoid arthritis and other musculoskeletal disorders.
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